Advertisement
Launched in 1993, the NASDAQ Biotechnology Index is ranked on asemi-annual basis in May and November and serves as the basis for the iSharesNASDAQ Biotechnology Fund (Amex: IBB). Securities included in the NASDAQBiotechnology Index must be listed on the NASDAQ National Market and beclassified according to the FTSE(TM) Global Classification System as eitherbiotechnology or pharmaceutical. Additionally, securities in the index mustmeet minimum requirements for market value, average daily share volume andseasoning as a public company, among other criteria. For more informationabout the NASDAQ Biotechnology Index, including eligibility criteria, visithttp://www.nasdaq.com.
Advertisement
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializingproducts based on the extracellular matrix for the drug delivery, oncology anddermatology markets. The company's portfolio of products and productcandidates is based on intellectual property covering the family of humanenzymes known as hyaluronidases. The company's Enhanze Technology is a noveldrug delivery platform designed to increase the absorption and dispersion ofbiologics. Its key partnerships are with Roche to apply Enhanze Technology toRoche's biological therapeutic compounds for up to 13 targets and with Baxterto apply Enhanze Technology to Baxter's biological therapeutic compound,GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval fortwo products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, foruse as an adjuvant to increase the absorption and dispersion of other injecteddrugs and fluids. HYLENEX is partnered with Baxter International Inc. TheCompany also has a number of different enzymes in its portfolio that aretargeting significant areas of unmet need.Halozyme Contact Investor Relations Contact David A. Ramsay Don Markley Chief Financial Officer Lippert/Heilshorn & Associates (858) 704-8260 (310) 691-7100 [email protected] [email protected]
SOURCE Halozyme Therapeutics, Inc.
